Navigation Links
Watson Confirms EMBEDA(R) Patent Challenge
Date:10/7/2011

PARSIPPANY, N.J., Oct. 7, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Morphine Sulfate and Naltrexone Hydrochloride Extended-release Capsules 30 mg/1.2 mg, 50 mg/2 mg, 60 mg/2.4 mg, 80 mg/3.2 mg, and 100 mg/4 mg.  Watson's Morphine Sulfate and Naltrexone Hydrochloride Capsules are generic versions of EMBEDA® Extended Release Capsules sold by King Pharmaceuticals, Inc., a wholly-owned subsidiary of Pfizer Inc. EMBEDA® is indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

Pfizer, King and Alpharma Pharmaceuticals LLC filed suit against Watson on October 6, 2011, in the United States District Court for the District of Delaware seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent Nos. 7,682,633; 7,682,634; and 7,815,934.  The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA for up to 30 months from the date the plaintiffs received notice of Watson's ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.

Based on available information, Watson believes it may be a "first applicant" to file an ANDA for the generic version of EMBEDA® and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity.

For the twelve months ending August 31, 2011, EMBEDA® had total U.S. sales of approximately $42 million according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is a leadin
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Watson Launches Generic FEMCON(R) Fe
2. Watson to Host Conference Call and Webcast to Discuss Third Quarter 2011 Earnings
3. Watson to Present at the Jefferies 2011 Global Healthcare Conference
4. Watson Confirms Amphastar Patent Lawsuit
5. Watson Pharmaceuticals Announces Approval of Amphastars Generic LOVENOX(R)
6. Watson to Present at the 2011 Bank of America Merrill Lynch Global Healthcare Conference
7. Watson to Present at the 2011 Morgan Stanley Global Healthcare Conference
8. Watsons Anda Distribution to Build 234,000 sq ft Pharmaceutical Warehouse and Distribution Facility in Olive Branch, DeSoto County, MS
9. Watson Enters into Agreement to Acquire Products Related to Perrigos Acquisition of Paddock Laboratories
10. Watson Second Quarter 2011 Net Revenue Exceeds $1 Billion; Non-GAAP EPS of $1.01
11. Watson Confirms JALYN™ Patent Challenge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 Minimally Invasive Devices Inc. ... device company, announced today that Mitsubishi Corporation has formally ... visualization system in Japan . MID ... Japan in the second half ... exclusive distributor for Karl Storz GMBH & Co. (endoscopic ...
(Date:8/19/2014)... , Aug. 19, 2014  Tokyo-based Atonarp ... A funding round led by Walden Riverwood Ventures ... the development of Atonarp,s Smart Spectrometer technology platform, ... The company has targeted the oil & gas ... "We are excited to partner with Atonarp ...
(Date:8/19/2014)...  Boehringer Ingelheim today announced that the U.S. ... the New Drug Application (NDA) for the fixed-dose ... the Respimat ® inhaler for the proposed ... obstruction in patients with chronic obstructive pulmonary disease ... olodaterol FDC will not be indicated to treat ...
Breaking Medicine Technology:Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8
(Date:8/19/2014)... 2014 Recently, Skmen.com, an outstanding company in ... bohemian dresses . In addition to this, the company ... Now, all of them are available at low rates, up ... product design and quality. Its beautiful bohemian outfits are available ... many others. Owing to its top quality clothes, reasonable prices ...
(Date:8/19/2014)... 19, 2014 Kars4Kids , a ... announced today its partnership with New York State Senator ... in the Bronx. The giveaway will take place in ... Crotona Park on August 22. , “With a ... believe properly preparing children for school with the necessary ...
(Date:8/19/2014)... has recently compared many popular hosting suppliers and announced ... recommended companies for webmasters who want to buy high ... an affordable price. , Both GoDaddy and iPage ... the lowest upfront costs (including some Joomla hosting products ... of options. , GoDaddy is a famous supplier ...
(Date:8/19/2014)... 19, 2014 Grande Naturals, LLC ... winner of the 2014 Independent Cosmetics Manufacturers & ... first place position in “Product Innovation; Product Color ... which also includes a lash enhancement serum, GrandeLINER™. ... lash-boosting technology. , This all-new eyeliner ...
(Date:8/19/2014)... HealthDay Reporter TUESDAY, ... be added to the list of possible harms related ... treat behavioral symptoms of dementia in older adults, a ... olanzapine (Zyprexa) are approved by the U.S. Food and ... serious mental disorders. They are also frequently used "off-label" ...
Breaking Medicine News(10 mins):Health News:2014 Bohemian Dresses Now for Sale at Skmen.com 2Health News:Backpack Giveaway Kars4Kids Partners with New York State Senator Gustavo Rivera to Prepare Bronx Students for New School Year 2Health News:Top10BestSEOHosting.com: Cheap Joomla Hosting Reviews Unveiled 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 3Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 2Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 3
... June 17 NeoMend, Inc. today announced,that its ... from the U.S. Food and Drug Administration,s (FDA) ... panel,s recommendation will be considered by the FDA ... (PMA) for ProGEL. The,panel,s recommendation for FDA approval ...
... BOSTON--Patients diagnosed with colon cancer who had abundant vitamin D ... follow-up period than those who were deficient in the vitamin, ... Institute. , The findings of the study -- the first ... patients -- merit further research, but it is too early ...
... Access to Personal ... Enrolls Nearly 1,000 Police Officers in MedeFile System During National ... ... Board: MDFI), a company specializing in,portable electronic medical records management solutions, today announced,that ...
... -- Research findings and innovative approaches offer the promise ... adults living with type 1 diabetes, according to researchers ... Forum in Washington D.C. , Type 1 diabetes is ... insulin-producing beta cells in the pancreas. It renders ...
... June 18 A CI head once noted that,"Competitive ... but the only,time you realize you need it is ... marketing space, most companies need competitive,intelligence to effectively deal ... insights are lacking that people begin to realize how,critical ...
... 18 Sunrise Senior Living,Inc. (NYSE: SRZ ), ... will present at the 2008 Jefferies 2nd Annual,Healthcare Conference ... 1:30 p.m.,Eastern Time. Sunrise will Web cast the presentation ... http://www.sunriseseniorliving.com ). A replay of the Web cast will ...
Cached Medicine News:Health News:NeoMend Receives FDA Panel's Recommendation for Approval of ProGEL(TM) Surgical Sealant 2Health News:Study links vitamin D to colon cancer survival 2Health News:MedeFile International Teams with Newark Fraternal Order of Police 2Health News:MedeFile International Teams with Newark Fraternal Order of Police 3Health News:MedeFile International Teams with Newark Fraternal Order of Police 4Health News:Science, hope for adults with type 1 diabetes focus of JDRF's Annual Global Diabetes Research Forum 2Health News:Science, hope for adults with type 1 diabetes focus of JDRF's Annual Global Diabetes Research Forum 3Health News:Build and Maintain an Effective Competitive Intelligence Group 2
... Based on decades of experience, the SSD-1000 ... ultrasound system. It uses our advanced technologies ... experience. Using the same technology as our ... imaging capabilities in a compact and mobile ...
... Using pulsed radiofrequncy current, ... system quickly heats and ablates ... it in minimal time., RF ... in open surgery, percutaneously, or ...
... a biologically based adhesive supplied as ... consisting of a liquid substrate and ... internal bleeding. When combined ... to a prepared wound and tenaciously ...
... (Human) achieves a secure clot, targeted to ... for hemostasis is needed, when control of ... ligature, and cautery, is ineffective or impractical., ... formulation of human Biologically Active Component (BAC) ...
Medicine Products: